Literature DB >> 26395553

RET and EDNRB mutation screening in patients with Hirschsprung disease: Functional studies and its implications for genetic counseling.

Titis Widowati1, Shamiram Melhem2, Suryono Y Patria1, Bianca M de Graaf2, Richard J Sinke3, Martijn Viel3, Jos Dijkhuis3, Ahmad H Sadewa4, Rochadi Purwohardjono5, Yati Soenarto1, Robert Mw Hofstra2, Yunia Sribudiani6.   

Abstract

Hirschsprung disease (HSCR) is a major cause of chronic constipation in children. HSCR can be caused by germline mutations in RET and EDNRB. Defining causality of the mutations identified is difficult and almost exclusively based on in silico predictions. Therefore, the reported frequency of pathogenic mutations might be overestimated. We combined mutation analysis with functional assays to determine the frequencies of proven pathogenic RET and EDNRB mutations in HSCR. We sequenced RET and EDNRB in 57 HSCR patients. The identified RET-coding variants were introduced into RET constructs and these were transfected into HEK293 cells to determine RET phosphorylation and activation via ERK. An exon trap experiment was performed to check a possible splice-site mutation. We identified eight rare RET-coding variants, one possible splice-site variant, but no rare EDNRB variants. Western blotting showed that three coding variants p.(Pr270Leu), p.(Ala756Val) and p.(Tyr1062Cys) resulted in lower activation of RET. Moreover, only two RET variants (p.(Ala756Val) and p.(Tyr1062Cys)) resulted in reduced ERK activation. Splice-site assays on c.1880-11A>G could not confirm its pathogenicity. Our data suggest that indeed almost half of the identified rare variants are proven pathogenic and that, hence, functional studies are essential for proper genetic counseling.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26395553      PMCID: PMC4867453          DOI: 10.1038/ejhg.2015.214

Source DB:  PubMed          Journal:  Eur J Hum Genet        ISSN: 1018-4813            Impact factor:   4.246


  30 in total

1.  Functional analysis of RET with Hirschsprung mutations affecting its kinase domain.

Authors:  T Iwashita; K Kurokawa; S Qiao; H Murakami; N Asai; K Kawai; M Hashimoto; T Watanabe; M Ichihara; M Takahashi
Journal:  Gastroenterology       Date:  2001-07       Impact factor: 22.682

2.  Chinese patients with sporadic Hirschsprung's disease are predominantly represented by a single RET haplotype.

Authors:  M-M Garcia-Barceló; M-H Sham; V C-H Lui; B L-S Chen; Y-Q Song; W-S Lee; S-K Yung; G Romeo; P K-H Tam
Journal:  J Med Genet       Date:  2003-11       Impact factor: 6.318

Review 3.  EDNRB/EDN3 and Hirschsprung disease type II.

Authors:  A S McCallion; A Chakravarti
Journal:  Pigment Cell Res       Date:  2001-06

4.  Analysis of the RET, GDNF, EDN3, and EDNRB genes in patients with intestinal neuronal dysplasia and Hirschsprung disease.

Authors:  R Gath; A Goessling; K M Keller; S Koletzko; W Coerdt; H Müntefering; S Wirth; R M Hofstra; L Mulligan; C Eng; A von Deimling
Journal:  Gut       Date:  2001-05       Impact factor: 23.059

5.  RET and GDNF gene scanning in Hirschsprung patients using two dual denaturing gel systems.

Authors:  R M Hofstra; Y Wu; R P Stulp; P Elfferich; J Osinga; S M Maas; L Siderius; A S Brooks; J J vd Ende; V M Heydendael; R S Severijnen; K M Bax; C Meijers; C H Buys
Journal:  Hum Mutat       Date:  2000       Impact factor: 4.878

6.  Intrinsic susceptibility to misfolding of a hot-spot for Hirschsprung disease mutations in the ectodomain of RET.

Authors:  Svend Kjaer; Carlos F Ibáñez
Journal:  Hum Mol Genet       Date:  2003-07-15       Impact factor: 6.150

7.  A new germline RET mutation apparently devoid of transforming activity serendipitously discovered in a patient with atrophic autoimmune thyroiditis and primary ovarian failure.

Authors:  G Orgiana; G Pinna; A Camedda; V De Falco; M Santoro; R M Melillo; R Elisei; C Romei; S Lai; C Carcassi; S Mariotti
Journal:  J Clin Endocrinol Metab       Date:  2004-10       Impact factor: 5.958

8.  Highly recurrent RET mutations and novel mutations in genes of the receptor tyrosine kinase and endothelin receptor B pathways in Chinese patients with sporadic Hirschsprung disease.

Authors:  Mercè Garcia-Barceló; Mai-Har Sham; Wing-Shan Lee; Vincent Chi-Hang Lui; Benedict Ling-Sze Chen; Kenneth Kak-Yuen Wong; Joyce Suet-Wan Wong; Paul Kwong-Hang Tam
Journal:  Clin Chem       Date:  2003-11-18       Impact factor: 8.327

9.  Mutation analysis of the RET receptor tyrosine kinase in Hirschsprung disease.

Authors:  M Angrist; S Bolk; B Thiel; E G Puffenberger; R M Hofstra; C H Buys; D T Cass; A Chakravarti
Journal:  Hum Mol Genet       Date:  1995-05       Impact factor: 6.150

10.  The modifier role of RET-G691S polymorphism in hereditary medullary thyroid carcinoma: functional characterization and expression/penetrance studies.

Authors:  Carla Colombo; Emanuela Minna; Maria Grazia Rizzetti; Paola Romeo; Daniele Lecis; Luca Persani; Piera Mondellini; Marco A Pierotti; Angela Greco; Laura Fugazzola; Maria Grazia Borrello
Journal:  Orphanet J Rare Dis       Date:  2015-03-01       Impact factor: 4.123

View more
  8 in total

Review 1.  Advances in understanding functional variations in the Hirschsprung disease spectrum (variant Hirschsprung disease).

Authors:  S W Moore
Journal:  Pediatr Surg Int       Date:  2016-12-17       Impact factor: 1.827

2.  Deviation from baseline mutation burden provides powerful and robust rare-variants association test for complex diseases.

Authors:  Lin Jiang; Hui Jiang; Sheng Dai; Ying Chen; Youqiang Song; Clara Sze-Man Tang; Shirley Yin-Yu Pang; Shu-Leong Ho; Binbin Wang; Maria-Mercedes Garcia-Barcelo; Paul Kwong-Hang Tam; Stacey S Cherny; Mulin Jun Li; Pak Chung Sham; Miaoxin Li
Journal:  Nucleic Acids Res       Date:  2022-04-08       Impact factor: 16.971

3.  Novel Causative RET Mutation in a Japanese Family with Hirschsprung's Disease: Case Report and Factors Impacting Disease Severity.

Authors:  Tsukasa Higuchi; Kazuki Yoshizawa; Tomoko Hatata; Katsumi Yoshizawa; Shigeru Takamizawa; Jun Kobayashi; Noriko Kubota; Eiko Hidaka
Journal:  J Pediatr Genet       Date:  2020-10-05

4.  Outcome of Clinical Genetic Testing in Patients with Features Suggestive for Hereditary Predisposition to PTH-Mediated Hypercalcemia.

Authors:  Shafaq Khairi; Jenae Osborne; Michelle F Jacobs; Gregory T Clines; Barbra S Miller; David T Hughes; Tobias Else
Journal:  Horm Cancer       Date:  2020-08-05       Impact factor: 3.869

5.  A Novel Zebrafish ret Heterozygous Model of Hirschsprung Disease Identifies a Functional Role for mapk10 as a Modifier of Enteric Nervous System Phenotype Severity.

Authors:  Tiffany A Heanue; Werend Boesmans; Donald M Bell; Koichi Kawakami; Pieter Vanden Berghe; Vassilis Pachnis
Journal:  PLoS Genet       Date:  2016-11-30       Impact factor: 5.917

6.  Functional Studies on Novel RET Mutations and Their Implications for Genetic Counseling for Hirschsprung Disease.

Authors:  Hui Wang; Qi Li; Zhen Zhang; Ping Xiao; Long Li; Qian Jiang
Journal:  Front Genet       Date:  2019-10-08       Impact factor: 4.599

7.  Germline RET Leu56Met Variant Is Likely Not Causative of Multiple Endocrine Neoplasia Type 2.

Authors:  Anna Reimer Hansen; Line Borgwardt; Åse Krogh Rasmussen; Christian Godballe; Morten Møller Poulsen; Filipe G Vieira; Jes Sloth Mathiesen; Maria Rossing
Journal:  Front Endocrinol (Lausanne)       Date:  2021-12-01       Impact factor: 5.555

8.  Sequence characterization of RET in 117 Chinese Hirschsprung disease families identifies a large burden of de novo and parental mosaic mutations.

Authors:  Qian Jiang; Yang Wang; Qi Li; Zhen Zhang; Ping Xiao; Hui Wang; Na Liu; Jian Wu; Feng Zhang; Aravinda Chakravarti; Wei Cai; Long Li
Journal:  Orphanet J Rare Dis       Date:  2019-10-30       Impact factor: 4.123

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.